CERVOMED INC (CRVO) Stock Analyst Ratings
NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock
ChartMill assigns a Buy % Consensus number of 73% to CRVO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.14. This target is 1007.34% above the current price.
CRVO was analyzed by 14 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about CRVO.
In the last month the buy percentage fell by 9 points. So the trust of analysts is decreasing.
CRVO was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-12-11 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2024-12-11 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-10 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2024-12-10 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-12-05 | Roth MKM | Initiate | Buy |
| 2024-12-05 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-18 | D. Boral Capital | Initiate | Buy |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-18 | Chardan Capital | Initiate | Buy |
| 2024-07-26 | Morgan Stanley | Initiate | Overweight |
| 2024-07-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-07-08 | Brookline Capital | Initiate | Buy |
| 2024-05-29 | Jones Trading | Initiate | Buy |
| 2024-04-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-02-15 | Canaccord Genuity | Initiate | Buy |